Journal of Clinical Pharmacy and Therapeutics

Cover image for Vol. 41 Issue 4

Edited By: A. Li Wan Po

Impact Factor: 1.833

ISI Journal Citation Reports © Ranking: 2015: 163/253 (Pharmacology & Pharmacy)

Online ISSN: 1365-2710

Recently Published Issues

See all

Free review articles

A systematic review of the prevalence and incidence of prescribing errors with high-risk medicines in hospitals

Bundle interventions used to reduce prescribing and administration errors in hospitalized children: a systematic review

Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck

Pharmacy-led medication reconciliation programmes at hospital transitions: a systematic review and meta-analysis

Pharmacist-involved care for patients with heart failure and acute coronary syndrome: a systematic review with qualitative and quantitative meta-analysis

Effectiveness of the STOPP/START (Screening Tool of Older Persons' potentially inappropriate Prescriptions/Screening Tool to Alert doctors to the Right Treatment) criteria: systematic review and meta-analysis of randomized controlled studies

Systematic review of red yeast rice compared with simvastatin in dyslipidaemia

Effect of Aloe vera on glycaemic control in prediabetes and type 2 diabetes: a systematic review and meta-analysis

Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?

Quetiapine safety in older adults: a systematic literature review

Management of opioid-induced constipation in pregnancy: a concise review with emphasis on the PAMORAs

Kawasaki disease: a comprehensive review of treatment options

Hyponatraemia induced by terlipressin: a case report and literature review

The role of abuse-deterrent formulations in countering opioid misuse and abuse

Inappropriate prescribing of intravenous fluid in adult inpatients-a literature review of current practice and research

Systematic review of topical amitriptyline for the treatment of neuropathic pain

Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma

Preserving the peritoneal membrane in long-term peritoneal dialysis patients

The role of azithromycin in healthcare-associated pneumonia treatment

Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection

Employment of vasopressin receptor antagonists in management of hyponatraemia and volume overload in some clinical conditions

Heme iron polypeptide for the management of anaemia of chronic kidney disease

Recently Published Articles

  1. Anticholinergic medicines in an older primary care population: a cross-sectional analysis of medicines’ levels of anticholinergic activity and clinical indications

    P. J. Magin, S. Morgan, A. Tapley, C. McCowan, L. Parkinson, K. M. Henderson, C. Muth, M. S. Hammer, D. Pond, K. E. Mate, N. A. Spike, L. A. McArthur and M. L. van Driel

    Version of Record online: 27 JUN 2016 | DOI: 10.1111/jcpt.12413

    Thumbnail image of graphical abstract

    Level 1, Level 2 and 3 combined, and total anticholinergic medicines, by ICPC-2 chapter.

  2. You have free access to this content
    Network meta-analysis of Chinese herb injections combined with FOLFOX chemotherapy in the treatment of advanced colorectal cancer (pages 383–391)

    L. Ge, Y-f. Wang, J-h. Tian, L. Mao, J. Zhang, J-h. Zhang, X-p. Shen and K-h. Yang

    Version of Record online: 24 JUN 2016 | DOI: 10.1111/jcpt.12410

    Thumbnail image of graphical abstract

    We firstly carried out a network meta-analysis to assess the clinical efficacy and safety of Chinese herb injections (CHIs) combined oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) for advanced colorectal cancer (CRC) to determine which is the best CHIs. We included 63 studies involving 4837 patients. Based on currently limited evidence, aidi, shenqifuzheng and compound matrine were superior to other CHIs in patients of FOLFOX chemotherapy for advanced CRC.

  3. Utilization of antithrombotic therapy for stroke prevention in atrial fibrillation: a cross-sectional baseline analysis in general practice (pages 432–440)

    B. Bajorek, P. J. Magin, S. Hilmer and I. Krass

    Version of Record online: 24 JUN 2016 | DOI: 10.1111/jcpt.12409

    Thumbnail image of graphical abstract

    There has been an encouraging temporal improvement in the utilization of antithrombotic therapy for stroke prevention in AF within general practice. Anticoagulants (mostly warfarin) are now utilized as the mainstay therapy, although a small proportion of patients continue to be prescribed antiplatelet agents. Importantly, the impact of patient age on the use of antithrombotics appears to have significantly reduced. Consideration needs to be given to the potential impact of the NOACs and their scope of use given the increased utilization of antithrombotic therapy.

  4. In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696) (pages 424–431)

    S. Ayalasomayajula, Y. Han, T. Langenickel, K. Malcolm, W. Zhou, I. Hanna, N. Alexander, A. Natrillo, B. Goswami, M. Hinder and G. Sunkara

    Version of Record online: 19 JUN 2016 | DOI: 10.1111/jcpt.12408

    Thumbnail image of graphical abstract

    In vitro evaluation showed that sacubitril (a neprilysin inhibitor prodrug) inhibited OATP1B1 and OATP1B3 transporter, with IC50 less than clinically observed peak concentrations. An open-label, fixed-sequence clinical study in 26 healthy subjects evaluating the effect of sacubitril/valsartan on the exposure of simvastatin and its active metabolite simvastatin acid (one of most sensitive substrate of OATP1B1) showed that the OATP-inhibitory effect of sacubitril did not translate into changes in key pharmacokinetic parameters of simvastatin acid in vivo. This could possibly be explained by rapid clearance of sacubitril from the circulation (T1/2 of approximately 1 h) and its high plasma protein binding (97%).

  5. Warfarin-induced calciphylaxis in patients with normal renal function (pages 449–452)

    L. Huilaja, M. Turpeinen, H. Tokola, H. Kauma, K. Tasanen and R. Ikäheimo

    Version of Record online: 19 JUN 2016 | DOI: 10.1111/jcpt.12411

    Thumbnail image of graphical abstract

    Calciphylaxis is a rare and potentially life-threatening cause of skin necrosis and is poorly recognized by clinicians in non-uraemic patients. We report five cases of warfarin-induced calciphylaxis in patients with normal renal function. In four cases, sodium thiosulphate was successfully used as a treatment.

SEARCH

SEARCH BY CITATION